Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

U Lassen; K Osterlind; M Hansen; P Dombernowsky; B Bergman; H H Hansen

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

U Lassen, K Osterlind, M Hansen, P Dombernowsky, B Bergman, H H Hansen

244 Citations (Scopus)

Abstract

PURPOSE: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981.

PATIENTS AND METHODS: A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics.

RESULTS: Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%).

CONCLUSION: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.

Original language	English
Journal	Journal of Clinical Oncology
Volume	13
Issue number	5
Pages (from-to)	1215-20
Number of pages	6
ISSN	0732-183X
Publication status	Published - May 1995

Keywords

Alkaline Phosphatase
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Small Cell
Combined Modality Therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
L-Lactate Dehydrogenase
Lung Neoplasms
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Peripheral Nervous System Diseases
Prognosis
Regression Analysis
Risk Factors
Survival Rate
Survivors
Treatment Outcome
Clinical Trial
Controlled Clinical Trial
Journal Article
Multicenter Study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9d87597926c04da3a9c58f2ba6b1b950,

title = "Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients",

abstract = "PURPOSE: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981.PATIENTS AND METHODS: A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics.RESULTS: Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%).CONCLUSION: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.",

keywords = "Alkaline Phosphatase, Antineoplastic Agents, Biomarkers, Tumor, Carcinoma, Small Cell, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, L-Lactate Dehydrogenase, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Peripheral Nervous System Diseases, Prognosis, Regression Analysis, Risk Factors, Survival Rate, Survivors, Treatment Outcome, Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study",

author = "U Lassen and K Osterlind and M Hansen and P Dombernowsky and B Bergman and Hansen, {H H}",

year = "1995",

month = may,

language = "English",

volume = "13",

pages = "1215--20",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

TY - JOUR

T1 - Long-term survival in small-cell lung cancer

T2 - posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

AU - Lassen, U

AU - Osterlind, K

AU - Hansen, M

AU - Dombernowsky, P

AU - Bergman, B

AU - Hansen, H H

PY - 1995/5

Y1 - 1995/5

N2 - PURPOSE: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981.PATIENTS AND METHODS: A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics.RESULTS: Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%).CONCLUSION: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.

AB - PURPOSE: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981.PATIENTS AND METHODS: A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics.RESULTS: Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%).CONCLUSION: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.

KW - Alkaline Phosphatase

KW - Antineoplastic Agents

KW - Biomarkers, Tumor

KW - Carcinoma, Small Cell

KW - Combined Modality Therapy

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - L-Lactate Dehydrogenase

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Peripheral Nervous System Diseases

KW - Prognosis

KW - Regression Analysis

KW - Risk Factors

KW - Survival Rate

KW - Survivors

KW - Treatment Outcome

KW - Clinical Trial

KW - Controlled Clinical Trial

KW - Journal Article

KW - Multicenter Study

M3 - Journal article

C2 - 7738624

SN - 0732-183X

VL - 13

SP - 1215

EP - 1220

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

Abstract

Keywords

UN SDGs

Fingerprint

Cite this